Login to Your Account

RNAi still sizzling: Arrowhead seeks $104.2M for HBV drug

By Marie Powers
Staff Writer

Wednesday, February 19, 2014
Signaling the RNAi space remains a hot ticket, Arrowhead Research Corp. priced an underwritten offering of 5.5 million shares of common stock at $18.95 apiece, seeking to raise $104.225 million. The Pasadena, Calif.-based company granted the underwriters a 30-day option to purchase up to an additional 825,000 shares, potentially increasing the deal size by $15.6 million.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription